Ko G N, Jimerson D C, Wyatt R J, Bigelow L B
Neuropsychiatry Branch, National Institute of Mental Health, Bethesda, Md.
Arch Gen Psychiatry. 1988 Sep;45(9):842-6. doi: 10.1001/archpsyc.1988.01800330072009.
In a study of 14 drug-free schizophrenic patients and 22 healthy control subjects, the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) level appeared to be altered by changes in clinical state. Repeated sampling in schizophrenic patients showed that plasma MHPG values were elevated in high-psychosis phases in comparison with metabolite levels at times of lower psychosis. There was a nonsignificant trend toward higher MHPG levels in paranoid schizophrenic patients in comparison with patients who had undifferentiated schizophrenia. Paranoid schizophrenic patients had significantly elevated plasma MHPG levels in comparison with previously studied healthy controls. These findings suggested that alterations in the plasma MHPG level may reflect psychosis-related changes in norepinephrine function in schizophrenia.
在一项针对14名未服用药物的精神分裂症患者和22名健康对照者的研究中，血浆3-甲氧基-4-羟基苯乙二醇（MHPG）水平似乎会因临床状态的变化而改变。对精神分裂症患者的重复采样显示，与精神病症状较轻时的代谢物水平相比，在精神病症状严重阶段血浆MHPG值升高。与未分化型精神分裂症患者相比，偏执型精神分裂症患者的MHPG水平有升高的趋势，但差异无统计学意义。与先前研究的健康对照者相比，偏执型精神分裂症患者的血浆MHPG水平显著升高。这些发现表明，血浆MHPG水平的改变可能反映了精神分裂症中去甲肾上腺素功能与精神病相关的变化。
